Evidence map›Paper›PMID 38362340›Full record

ArticleJACC. Basic to translational science2024

Preservation of von Willebrand Factor Activity With the ModulHeart Device.

Gabriel Georges, François Trudeau, Jeannot Potvin, François Potus, Sandra Martineau, Philippe Généreux

Open access · goldAbstract read
In one paragraph

Article in JACC. Basic to translational science, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 2 countries.

Gabriel GeorgesQuebec Heart and Lung Institute, Quebec, Quebec, Canada.
François TrudeauPuzzle Medical Devices Inc., Montreal, Quebec, Canada.
Jeannot PotvinCentre Hospitalier de l'Université de Montréal, Montreal, Quebec, Canada.
François PotusQuebec Heart and Lung Institute, Quebec, Quebec, Canada.
Sandra MartineauQuebec Heart and Lung Institute, Quebec, Quebec, Canada.
Philippe GénéreuxGagnon Cardiovascular Institute, Morristown Medical Center, Morristown, New Jersey, USA.
Montreal Heart Institute · CACentre Hospitalier de l’Université de Montréal · CAMorristown Medical Center · USWalsh Medical Devices (Canada) · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

von Willebrand Factor (VWF) destruction is common with current heart pumps. This study evaluates VWF activity with ModulHeart, a novel device using 3 micropumps in parallel. In model 1, ModulHeart was compared with Impella devices in vitro. In model 2, 3 healthy swine received ModulHeart. Model 3 includes VWF data from patients who underwent protected percutaneous coronary intervention with ModulHeart. In models 1, 2, and 3, ModulHeart resulted in preservation of VWF, whereas there was a 27% and 19% reduction in VWF activity with the Impella CP and 5.0, respectively. ModulHeart features a unique design and demonstrated preservation of VWF activity.

Indexed as

gastrointestinal bleedingheart failureleft ventricular assist devicepreclinical studyvon Willebrand factor

Identifiers

PMID38362340
PMCPMC10864901
OpenAlexW4387330639

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.